Research outlook

Where progressive supranuclear palsy treatment is heading

Progressive supranuclear palsy · Updated Nov 14, 2026

Progressive supranuclear palsy (PSP) is a brain disease in which the tau protein builds up and damages areas that control balance, eye movement, speech, swallowing and thinking. It is often first mistaken for Parkinson disease; roughly 20,000 Americans have it, with a few thousand diagnosed each year, usually in their 60s. There is no approved treatment to slow it, and Parkinson drugs help little. Several drugs have failed, but a tau-lowering antisense drug is now in phase 3 and a new platform trial tests several drugs at once.

  1. Now

    Nov 2026

    Anti-tau antibodies reach their targetHappened 80.41% less free tau

    Bepranemab cut free tau in spinal fluid by 80.41% and was well tolerated.

    80.41%: reduction in free tau in spinal fluid.

    Setbacks for other approachesHappened

    AMX0035 showed no benefit and its trial was stopped; brain stimulation did not help symptoms.

    Early signals from a progranulin drugHappened

    AZP2006 was safe, with trends toward slower progression in a small trial.

  2. 6 months

    by May 2027

    An O-GlcNAcase inhibitorLikely

    Ferrer's FNP-223 PROSPER trial (241 people), testing a pill meant to stop tau clumping, finishes November 2026.

  3. 12 months

    by Nov 2027

    siRNA to lower tauPossible

    Arrowhead's ARO-MAPT, an injection that lowers tau production, is in early trials (160 people, due June 2027).

  4. 3 years

    by late 2029

    Restoring brain cell energyLong shot

    NADAPT (330 people) tests nicotinamide riboside, a vitamin B3 form; due December 2028.

    Testing several drugs at oncePossible

    The PSP Trial Platform (440 people) tests the AADvac1 tau vaccine and LM11A-31 against a shared placebo; due September 2030.

  5. 5 years

    by late 2031

    The first phase 3 of a tau-lowering drugPossible 80.41% less free tau (bepranemab)

    Novartis' NIO752, an antisense drug injected into the spinal fluid to reduce tau production, is in phase 3 (300 people, due July 2029).

    80.41%: reduction in free tau in spinal fluid.

Happened Likely Possible Long shot

The research paths

Rising

Lowering tau production

Details and 2 trialsHide

Antisense and siRNA drugs that reduce how much tau the brain makes.

WatchNIO752 phase 3; ARO-MAPT.

Active

Targeting tau protein

80.41% less free tau
Details and 3 trialsHide
Mixed

Protecting brain cells

Details and 3 trialsHide

Borrowed from other conditions

From Alzheimer's disease research

Tau antisense and siRNA

Phase 3

Tau-lowering drugs also being tested in Alzheimer's disease.

From Parkinson disease research

Nicotinamide riboside

Phase 2

A vitamin B3 form tested to support brain cell energy.

From ALS

AMX0035

Stopped

Tested in PSP after ALS; withdrawn from the ALS market in 2024.

Open to join now

See every recruiting PSP trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Nov 2026
Tributyrin (virtual trial)Protecting brain cells
May 2027
ARO-MAPT-SC, a tau-lowering siRNALowering tau production
Jun 2027
Nicotinamide riboside (NADAPT)Protecting brain cells
Dec 2028
Jul 2029
Sep 2030
Sep 2030
PSP Platform regimen B: LM11A-31Protecting brain cells
Sep 2030

What just happened

Progranulin drug safe, with early signals

AZP2006, Movement Disorders.

AMX0035 trial stopped for lack of benefit

ORION.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See PSP trials recruiting now →

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.